GNLX
GNLX
NASDAQ · Biotechnology

Genelux Corp

$1.96
+0.14 (+7.69%)
Financial Highlights (FY 2026)
Revenue
8.5K
Net Income
-36,866,507
Gross Margin
—
Profit Margin
-401,812.5%
Rev Growth
-91.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 58.3% 58.3%
Operating Margin -415,175.0% -373,658.7% -22.4% -22.6%
Profit Margin -401,812.5% -381,721.9% -22.1% -17.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 8.5K 95.1K 62.40M 61.85M
Gross Profit — — 36.39M 36.07M
Operating Income -35,401,972 -355,203,732 -14,003,493 -13,961,219
Net Income -36,866,507 -369,898,063 -13,759,336 -10,609,098
Gross Margin — — 58.3% 58.3%
Operating Margin -415,175.0% -373,658.7% -22.4% -22.6%
Profit Margin -401,812.5% -381,721.9% -22.1% -17.2%
Rev Growth -91.0% -91.0% +12.2% +11.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 27.99M 31.26M
Total Equity — — 51.92M 51.92M
D/E Ratio — — 0.54 0.60
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -37,808,741 -400,427,022 -15,040,886 -15,866,697
Free Cash Flow — — -13,384,851 -9,996,517